Sponsor hub
Shire clinical trial failures
Review 44 stopped clinical trials from Shire, including disease areas, phases, and classified stop reasons.
This page groups real ClinicalTrials.gov-derived stopped trial records. The strongest added signal is the stop-reason classification: 4 of these records are likely biological failure signals, while the rest may reflect operational, strategic, regulatory, funding, enrollment, or unclear stop reasons.
Dominant stop reasons
- OPERATIONAL
- 20
- OTHER/UNKNOWN
- 20
- EFFICACY/FUTILITY
- 4
Notable sponsors
- Shire
- 44
Related phases
- Phase III
- 24
- Phase II
- 11
- Phase I
- 5
- Phase IV
- 4
Crawlable stopped-trial records
Open ExploreShowing up to 44 representative records from this slice. Each link opens the trial detail page with source attribution and stop-reason context.
Phase I Healthy Volunteers trial by Shire. Stop reason: EFFICACY/FUTILITY.
The study was stopped because based on the planned interim analysis of the data of Part 1, palatability of both pediatric formulations was not acceptable.
Phase III Eosinophilic Esophagitis (EoE) trial by Shire. Stop reason: OPERATIONAL.
Sponsor decision
Phase III Fabry Disease trial by Shire. Stop reason: OPERATIONAL.
Study closed due to enrolment challenges, not for any safety issues
Phase III Chronic Hypoparathyroidism trial by Shire. Stop reason: OPERATIONAL.
Business decision
Phase III Hypoparathyroidism trial by Shire. Stop reason: OTHER/UNKNOWN.
The study was terminated due to Takeda commercial Natpara recall.
Phase III Crohn's Disease trial by Shire. Stop reason: OPERATIONAL.
Sponsor decision to discontinue the SHP647 (ontamalimab) clinical trial development program for inflammatory bowel diseases (IBD) early.
Phase II Acute Adenoviral Conjunctivitis trial by Shire. Stop reason: OTHER/UNKNOWN.
No stop-reason text available in the compact dataset.
Phase IV Anemia trial by Shire. Stop reason: OTHER/UNKNOWN.
The termination of the study is not linked to a product recall or result of any safety signal. Rather it was sponsor's commercial decision to withdraw the MA
Phase III Attention Deficit Hyperactivity Disorder trial by Shire. Stop reason: OPERATIONAL.
This study was stopped by the sponsor before enrollment based on a non-safety related corporate decision.
Phase II Iron Overload Due to Repeated Red Blood Cell Transfusions trial by Shire. Stop reason: OTHER/UNKNOWN.
This study was terminated due to treatment stop resulting in an inability to draw conclusions from the data. Evaluation of nonclinical rat findings is ongoing.
Phase IV Hypotension, Orthostatic trial by Shire. Stop reason: OPERATIONAL.
Study was terminated due to poor enrollment
Phase II Iron Overload Due to Repeated Red Blood Cell Transfusions trial by Shire. Stop reason: OTHER/UNKNOWN.
This study was terminated due to treatment stop resulting in an inability to draw conclusions from the data. Evaluation of nonclinical rat findings is ongoing.
Phase III Schizophrenia trial by Shire. Stop reason: OPERATIONAL.
Study was discontinued due to non-safety related business prioritization decisions. No subjects were randomized.
Phase III Schizophrenia trial by Shire. Stop reason: OPERATIONAL.
Study was discontinued due to non-safety related business prioritization decisions. No subjects were randomized
Phase III Schizophrenia trial by Shire. Stop reason: OPERATIONAL.
Study was discontinued due to non-safety related business prioritization decisions. No subjects were randomized.
Phase III Anemia trial by Shire. Stop reason: OTHER/UNKNOWN.
The termination of the study is not linked to a product recall or result of any safety signal. Rather it was sponsor's commercial decision to withdraw the MA
Phase I Sanfilippo Syndrome trial by Shire. Stop reason: OTHER/UNKNOWN.
Completion of follow-up period
Phase III Adenoviral Conjunctivitis trial by Shire. Stop reason: OPERATIONAL.
Sponsor decision, unrelated to safety
Phase III Ulcerative Colitis trial by Shire. Stop reason: OPERATIONAL.
Sponsor decision to discontinue the SHP647 (ontamalimab) clinical trial development program for inflammatory bowel diseases (IBD) early.
Phase II Transfusional Iron Overload trial by Shire. Stop reason: OTHER/UNKNOWN.
This study was terminated due to treatment stop resulting in an inability to draw conclusions from the data. Evaluation of nonclinical rat findings is ongoing.
Phase III Major Depressive Disorder trial by Shire. Stop reason: OTHER/UNKNOWN.
SPD489 failed to demonstrate a benefit as adjunctive treatment to antidepressants. Termination was not related to any new safety findings.
Phase III Non-cancer Pain trial by Shire. Stop reason: OTHER/UNKNOWN.
The study was stopped by the sponsor based on a non-safety related business priority decision
Phase II ACE Inhibitor Induced Angioedema trial by Shire. Stop reason: EFFICACY/FUTILITY.
Interim analysis suggested a trend favoring ecallantide; observed response rate to placebo was substantially higher than described in medical literature.
Phase II Sanfilippo Syndrome trial by Shire. Stop reason: OTHER/UNKNOWN.
Completion of follow-up period
Phase II Gastroesophageal Reflux Disease trial by Shire. Stop reason: OPERATIONAL.
This study was terminated early due to recruitment difficulties. There were no safety concerns.
Phase III Adenoviral Conjunctivitis trial by Shire. Stop reason: OPERATIONAL.
Sponsor decision, unrelated to safety
Phase I Healthy trial by Shire. Stop reason: OTHER/UNKNOWN.
The study was stopped by the sponsor based on a non-safety related business priority decision.
Phase II Arteriovenous Graft trial by Shire. Stop reason: OPERATIONAL.
Development of SRM003 was discontinued based on portfolio prioritization.
Phase II Late Infantile Metachromatic Leukodystrophy trial by Shire. Stop reason: EFFICACY/FUTILITY.
Terminated prior to planned completion date due to lack of efficacy.
Phase III ADHD trial by Shire. Stop reason: OTHER/UNKNOWN.
Cancellation was not safety related but a shift in study priorities for Shire.
Phase III Attention Deficit Hyperactivity Disorder (ADHD) trial by Shire. Stop reason: OTHER/UNKNOWN.
The study was stopped due to efficacy reasons.
Phase III Negative Symptoms of Schizophrenia trial by Shire. Stop reason: OPERATIONAL.
Study was discontinued due to non-safety related business prioritization decisions
Phase I Healthy trial by Shire. Stop reason: OTHER/UNKNOWN.
This study was withdrawn until the evaluation of the nonclinical rat findings is complete.
Phase II Transfusional Iron Overload trial by Shire. Stop reason: OTHER/UNKNOWN.
This study was withdrawn until the evaluation of the nonclinical rat findings is complete.
Phase III Acute Otitis Externa trial by Shire. Stop reason: OTHER/UNKNOWN.
No stop-reason text available in the compact dataset.
Phase III Acute Fungal Otitis Externa trial by Shire. Stop reason: OTHER/UNKNOWN.
No stop-reason text available in the compact dataset.
Phase IV Kidney Diseases trial by Shire. Stop reason: OPERATIONAL.
This study was stopped by the sponsor based on a non-safety related corporate decision
Phase II Hereditary Angioedema (HAE) trial by Shire. Stop reason: OTHER/UNKNOWN.
No stop-reason text available in the compact dataset.
Phase III Crohn's Disease trial by Shire. Stop reason: OPERATIONAL.
Sponsor decision to discontinue the SHP647 (ontamalimab) clinical trial development program for inflammatory bowel diseases (IBD) early.
Phase III Crohn's Disease trial by Shire. Stop reason: OPERATIONAL.
Sponsor decision to discontinue the SHP647 (ontamalimab) clinical trial development program for inflammatory bowel diseases (IBD) early.
Phase III Ulcerative Colitis trial by Shire. Stop reason: OPERATIONAL.
Sponsor decision to discontinue the SHP647 (ontamalimab) clinical trial development program for inflammatory bowel diseases (IBD) early.
Phase I COVID-19 Pneumonia trial by Shire. Stop reason: OPERATIONAL.
Study was withdrawn due to challenges in site recruitment and lack of patient enrollment
Phase IV Chronic Obstructive Pulmonary Disease trial by Shire. Stop reason: OTHER/UNKNOWN.
Reevaluation of development strategy
Phase III Acute Antibody-Mediated Rejection (AMR) trial by Shire. Stop reason: EFFICACY/FUTILITY.
Following a pre-scheduled interim analysis performed by the DMC, it was determined that the study met the pre-specified criteria for futility.